Gordon Moody

Title: Gordon Moody: Innovator in Cancer Treatment

Introduction

Gordon Moody is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. With a total of 2 patents, Moody's work focuses on advanced therapeutic methods that harness the power of chimeric antigen receptors.

Latest Patents

Moody's latest patents include groundbreaking inventions aimed at improving cancer treatment. The first patent, titled "Compositions and methods of treating cancer with chimeric antigen receptors," relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells. The second patent, "Bispecific PD-1 and TIGIT binding proteins and uses thereof," involves binding proteins, including antibodies, that target Programmed Death-1 (PD-1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT). This patent also provides compositions comprising such binding proteins and nucleic acid molecules encoding them, along with methods for treating various disorders using these proteins.

Career Highlights

Throughout his career, Gordon Moody has worked with prominent companies in the pharmaceutical industry, including AstraZeneca and MedImmune Limited. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer treatment.

Collaborations

Moody has collaborated with several talented individuals in his field, including Maria Letizia Giardino Torchia and Michael Glen Overstreet. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Gordon Moody's contributions to cancer treatment through his innovative patents highlight his dedication to improving patient outcomes. His work continues to inspire advancements in the medical field, showcasing the importance of innovation in addressing complex health challenges.